3rd Annual Conference
2013
The Third Annual Imaging and Flow Cytometry Research Day was held on Wednesday, September 18th and was a huge success! Over 200 registrants and 21 vendors participated in the event.
Below are the featured presentations and abstracts from the 2013 Imaging and Flow Cytometry Research Day. Please click on the links to watch the full presentations and feel free to contact the presenters with any questions.
Brent Wood, MD, PhD
Brent Wood, obtained his MD and PhD from Loma Linda University followed by a residency in Anatomic and Clinical Pathology at the University of Washington in Seattle. After a fellowship in Hematopathology at the University of Washington, Dr. Wood accepted a faculty position in the Department of Laboratory Medicine at the University of Washington where he is currently Professor and Director of the Hematopathology Laboratory. His responsibilities include extensive clinical service work and teaching Hematopathology to medical technology students, medical students, residents and fellows. Flow cytometry is an area of particular interest for Dr. Wood and he is responsible for implementing the first use of 9 and 10 color flow cytometry in the clinical laboratory and exploiting its potential for the identification of minimal residual disease in acute lymphoid and myeloid leukemia. His laboratory serves as one of two national reference laboratories for the identification of minimal residual disease in childhood acute lymphoblastic leukemia for the Children's Oncology Group and is involved in similar protocols with the Southwest Oncology Group. Dr. Wood lectures both nationally and internationally on clinical applications of flow cytometry and is President of the International Clinical Cytometry Society.
Robert Sutherland, MsC
Robert Sutherland,obtained a Master’s Degree in Biochemistry from the University of London England in 1975 while working with Dr. Mel Greaves at the Imperial Cancer Research Fund. I moved to the Toronto General Hospital in 1984. I became an Assistant Professor in 1989 (Dept of Medicine, University of Toronto), Associate Professor in 1997, and Full Professor in 2009.
My early research interests included elucidating the structural characteristics of variety of cell surface molecules associated with normal and malignant cellular phenotypes including CD10, CD71, CD24, CD7 CD109 and CD34. My work studying the CD34 antigen led to the development of a new Flow Cytometric method to enumerate CD34+ cells. In 1996 this evolved into a clinical Guideline for ISHAGE (Int’l Soc Hematotherapy and Graft Evaluation). The ‘single platform’ variant of this is the most widely used method to assess graft adequacy in the bone marrow transplant setting and is embodied in several National and International Guidelines for graft assessment by Flow Cytometry. This work led to the Wallace H. Coulter Distinguished Lecture Award in 2006, “to recognize his lifetime contribution to the science, education and practice of Clinical Cytometry.”
Using primitive (CD34+) cells as an immunogen, we developed 4 monoclonal antibodies to a novel cell-surface antigen also present on activated T-lymphoblasts, activated platelets and endothelial cells. Using our antibodies, the Vth and VIth HLDA workshops designation this molecule CD109. We subsequently showed that CD109 is expressed on purified CD34+ cells and that the CD109+ fraction included progenitors of megakaryocytes, myelo-erythroid cells and pluripotent hematopoietic stem cells. Most significantly, we also showed that the CD109+ subset of CD34+ cells included the most primitive pluripotent stem cells in normal bone marrow. A US patent (#5,655,557) was issued based upon this work. We have immunopurified CD109 and obtained amino-acid sequence, thereby facilitating the cloning of the human CD109 cDNA. This has also allowed us to elucidate the molecular nature of the Gov platelet alloantigen system that is associated with CD109. A US patent (#7700613) was issued based upon this work.
As part of my duties as the Technical Director of the University Health Network Clinical Flow Cytometry Facility to the Clinical Flow Cytometry Laboratory at Toronto General Hospital, I develop new flow cytometric assays for deployment in the clinical laboratory. We have developed a number of clinical flow cytometric assays for the detection of Glycophosphatidyl-inositol (GPI)-linked structures that are lacking in Paroxysmal Nocturnal Hemoglobinuria and related disorders like Aplastic Anemia. I co-authored the recent ICCS Guidelines for the diagnosis of this rare disease by flow cytometry.
I am a member of the Canadian Bone Marrow Transplant Group Laboratory Committee. I serve on the Council of the International Clinical Cytometry Society. I have published 90 peer-reviewed articles, 14 Reviews, 9 Editorials and 11 Technical Monographs.
Geraldine Gaush, PhD
Geraldine Guasch is an Assistant Professor of Pediatrics in the Department of Developmental Biology. She received a BS/MS (diploma) in Biochemistry from University of Montpellier, France in 1997. She then moved to University of Aix-Marseille, France in 1997 and received her Ph.D. in Immunology/Oncology in January 2002. She received a Human Frontier Science Program Post-doctoral Fellowship in 2002 while at Rockefeller University in New York City. She joined Cincinnati Children’s Hospital in November 2008.
Geraldine Guasch has recently been named the 2011 Sidney Kimmel Scholar and the 2011 V Foundation Scholar.